Results 61 to 70 of about 944,744 (294)

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance

Nature Communications, 2017
γδ T cells are generally considered innate‐like lymphocytes. Here the authors sequence human γδ T cell receptors (TCR) to show focusing of the private Vδ1 TCR repertoire, suggesting that, unlike Vδ2 T cells, the Vδ1 T cell compartment has adaptive ...
Martin S. Davey, Carrie R. Willcox, Stephen P. Joyce, Kristin Ladell, Sofya A. Kasatskaya, James E. McLaren, Stuart Hunter, Mahboob Salim, Fiyaz Mohammed, David A. Price, Dmitriy M. Chudakov, Benjamin E. Willcox   +11 more
doaj   +1 more source

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel
John A Thompson, B. Schneider, J. Brahmer, Amaka Achufusi, Philippe Armand, Meghan K Berkenstock, S. Bhatia, L. Budde, S. Chokshi, M. Davies, Amro Elshoury, Yaron Gesthalter, A. Hegde, M. Jain, B. Kaffenberger, M. Lechner, Tianhong Li, A. Marr, S. McGettigan, J. McPherson, T. Medina, N. Mohindra, A. Olszanski, O. Oluwole, S. Patel, P. Patil, S. Reddy, Mabel Ryder, B. Santomasso, S. Shofer, J. Sosman, Yinghong Wang, V. G. Zaha, M. Lyons, M. Dwyer, Lisa E Hang   +35 more
semanticscholar   +1 more source

Addressing current challenges in cancer immunotherapy with mathematical and computational modeling

, 2017
The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating ...
Adler, Adam J., Konstorum, Anna, Laubenbacher, Reinhard, Vella, Anthony T.   +3 more
core   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem

Nanoscale Research Letters, 2020
Liver cancer is one of the most common malignancies worldwide. The RAF kinase inhibitors are effective in the treatment of hepatocellular carcinoma (HCC); therefore, inhibition of the BRAF/MEK/ERK pathway has become a new therapeutic strategy for novel ...
Yanling Liu, Manman Tan, Yujuan Zhang, Wei Huang, Liangliang Min, Shanshan Peng, Keng Yuan, Li Qiu, Weiping Min   +8 more
doaj   +1 more source

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Advancement of science, 2022
Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD).
Zhilin Li, Xiaoqin Lai, Shiqin Fu, Long Ren, Hao Cai, Hu Zhang, Zhongwei Gu, Xuelei Ma, Kui Luo   +8 more
semanticscholar   +1 more source

Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion

Cancer Immunology, Immunotherapy
Background Lymphocyte antigen 6 complex, locus E (Ly6E) has been initially demonstrated to involve in T cell activity and impair viral infectivity. Recently, high expression levels of Ly6E have been reported in tumor microenvironment (TME) of various ...
Lan Hailin, Chen Yiting, Wu Yue, Li Lijun, Zhang Renlu, Chen Yunhan, Zhu Yanyang, Zhang Qiuyu   +7 more
doaj   +1 more source

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

Nature Communications, 2021
Costimulation has been shown to be required for optimal activation of T cells and it could be delivered either in trans with respect to the source of CD3-TCR ligation or in cis on the same cell.
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, Maite Alvarez, José Medina-Echeverz, Ivan Cortés-Domínguez, Carlos Ortiz-de-Solorzano, Peter Ellmark, Sara Fritzell, Gabriela Hernandez-Hoyos, Michelle Hase Nelson, María Carmen Ochoa, Elixabet Bolaños, Doina Cuculescu, Patricia Jaúregui, Sandra Sanchez-Gregorio, Iñaki Etxeberria, María E. Rodriguez-Ruiz, Miguel F. Sanmamed, Álvaro Teijeira, Pedro Berraondo, Ignacio Melero   +21 more
doaj   +1 more source

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Journal of Hematology & Oncology
Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds.
Qiang Lu, Dongquan Kou, Shenghan Lou, M. Ashrafizadeh, A. Aref, Israel Cañadas, Yu Tian, Xiaojia Niu, Yuzhuo Wang, Pedram Torabian, Lingzhi Wang, Gautam Sethi, Vinay Tergaonkar, Franklin Tay, Zhennan Yuan, Peng Han   +15 more
semanticscholar   +1 more source